Phase I/II Trial of Cabazitaxel in Adult Patients With Recurrent Malignant Glioma
Latest Information Update: 13 Mar 2013
Price :
$35 *
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Adverse reactions
- 07 Mar 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 08 Jan 2013 New trial record